RIO DE JANEIRO, BRAZIL - COVAXX, a unit of United Biomedical Inc, said on Thursday it has received purchase commitments totaling US$2.8 billion to deliver more than 140 million doses of its potential Covid-19 vaccine to developing countries, including Brazil, Peru and Ecuador.
The multitope peptide-based vaccine is currently in early-stage trials in Taiwan, lagging some of the frontrunners in the race to develop a safe and effective vaccine.
The U.S.-based company signed an agreement in September with Brazilian laboratory and hospital group DASA S.A. to conduct mid-to-late stage trials for . . .